文献速递神经MRPET

神经影像界定脑内弥漫性胶质瘤的诊断准确性:一项Meta分析

Diagnostic Accuracy of Neuroimaging to Delineate Diffuse Gliomas within the Brain: A Meta-Analysis.
PubMed 文献 · AJNR Am J Neuroradiol · 2017-09-07

该系统评价纳入61项研究、1309例患者的3532个样本,采用分层汇总受试者工作特征方法分析成人弥漫性胶质瘤影像与组织病理学的相关性。整体诊断准确性以T2加权成像最佳(AUC 95.6%,假阳性率3.3%,真阳性率82%,诊断比值比152);低级别胶质瘤以T2加权成像为参考的准确性优于高级别胶质瘤以T1加权钆增强MR成像为参考。MR波谱和11C-甲硫氨酸PET在高级别胶质瘤中表现优于参考影像。

要点

  • 整体弥漫性胶质瘤界定以T2加权成像诊断准确性最佳,AUC为95.6%。
  • 低级别胶质瘤以T2加权成像为参考的AUC为89.0%,高于高级别胶质瘤以T1加权钆增强MR成像为参考的80.7%。
  • 高级别胶质瘤中MR波谱和11C-甲硫氨酸PET表现优于参考影像。

核心结论

  • 基于有限证据,常用影像对低级别胶质瘤的界定诊断准确性优于高级别胶质瘤,先进技术如MR波谱和PET提示可改善界定。

研究设计与样本

  • 系统检索成人弥漫性胶质瘤影像与组织病理学相关性研究,按质量标准纳入61项研究、1309例患者共3532个样本;采用分层汇总受试者工作特征方法分析,低级别与高级别胶质瘤分亚组分析。

诊断标准与关键数值

  • 弥漫性胶质瘤整体:T2加权成像的AUC 95.6%、假阳性率3.3%、真阳性率82%、诊断比值比152。
  • 低级别胶质瘤:以T2加权成像为参考的AUC 89.0%、假阳性率0.4%、真阳性率44.7%、诊断比值比205。
  • 高级别胶质瘤:以T1加权钆增强MR成像为参考的AUC 80.7%、假阳性率16.8%、真阳性率73.3%、诊断比值比14.8。
  • 高级别胶质瘤中MR波谱:AUC 85.7%、假阳性率35.0%、真阳性率85.7%、诊断比值比12.4。
  • 高级别胶质瘤中11C-甲硫氨酸PET:AUC 85.1%、假阳性率38.7%、真阳性率93.7%、诊断比值比26.6。

局限性

  • 数据中真阴性样本代表性不足,假阳性率可能不如真阳性率可靠。
  • 多模态影像数据不可获得。
  • 平均标准诊断准确性报告评分为13/25,提示报告质量欠佳。
  • 结论基于有限证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Brain imaging in diffuse glioma is used for diagnosis, treatment planning, and follow-up.

PURPOSE: In this meta-analysis, we address the diagnostic accuracy of imaging to delineate diffuse glioma.

DATA SOURCES: We systematically searched studies of adults with diffuse gliomas and correlation of imaging with histopathology.

STUDY SELECTION: Study inclusion was based on quality criteria. Individual patient data were used, if available.

DATA ANALYSIS: A hierarchic summary receiver operating characteristic method was applied. Low- and high-grade gliomas were analyzed in subgroups.

DATA SYNTHESIS: Sixty-one studies described 3532 samples in 1309 patients. The mean Standard for Reporting of Diagnostic Accuracy score (13/25) indicated suboptimal reporting quality. For diffuse gliomas as a whole, the diagnostic accuracy was best with T2-weighted imaging, measured as area under the curve, false-positive rate, true-positive rate, and diagnostic odds ratio of 95.6%, 3.3%, 82%, and 152. For low-grade gliomas, the diagnostic accuracy of T2-weighted imaging as a reference was 89.0%, 0.4%, 44.7%, and 205; and for high-grade gliomas, with T1-weighted gadolinium-enhanced MR imaging as a reference, it was 80.7%, 16.8%, 73.3%, and 14.8. In high-grade gliomas, MR spectroscopy (85.7%, 35.0%, 85.7%, and 12.4) and 11C methionine-PET (85.1%, 38.7%, 93.7%, and 26.6) performed better than the reference imaging.

LIMITATIONS: True-negative samples were underrepresented in these data, so false-positive rates are probably less reliable than true-positive rates. Multimodality imaging data were unavailable.

CONCLUSIONS: The diagnostic accuracy of commonly used imaging is better for delineation of low-grade gliomas than high-grade gliomas on the basis of limited evidence. Improvement is indicated from advanced techniques, such as MR spectroscopy and PET.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Verburg N, Hoefnagels FWA, Barkhof F, et al. Diagnostic Accuracy of Neuroimaging to Delineate Diffuse Gliomas within the Brain: A Meta-Analysis. AJNR Am J Neuroradiol. 2017. PMID: 28882867. doi:10.3174/ajnr.A5368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。